A pilot study of standard-dose rituximab, ifosfamide, carboplatin and etoposide (RICE) plus bortezomib (Velcade) in a dose-escalating fashion for patients with relapsed or primary refractory aggressive B-cell non-Hodgkin's lymphoma who are candidates for autologous stem cell transplant.

Status: Discontinued

Phase of Trial: Phase 0

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions

Most Recent Events

11 Apr 2012 Actual patient number is 7 as reported by ClinicalTrials.gov.
11 Apr 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.
11 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight